FDAapproval83% confidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (asthma) as asthma patients.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Respiratory · Asthma
- Sub-indication
- Asthma
Related signal: MHRA Approves First Lower-Carbon Beclometasone Inhalers for Asthma